Sutro Biopharma (STRO) — Financial Flexibility Index

Latest as of September 2025: -0.13x

Sutro Biopharma (STRO) has a Financial Flexibility Index of -0.13x as of September 2025. Free cash flow of $-37.94 Million (operating CF $-38.19 Million minus capex $251.00K) represents 0% of total liabilities ($296.93 Million). Also explore how fast is Sutro Biopharma growing its equity to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.13x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-37.94 Million
Operating CF − Capex

Total Liabilities

$296.93 Million
USD

Capital Expenditures

$251.00K
USD

Sutro Biopharma Financial Flexibility Index (2016–2024)

Historical Financial Flexibility Index trend for Sutro Biopharma across 9 annual periods. Check Sutro Biopharma (STRO) strategic asset index to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Sutro Biopharma (2016–2024)

Year-by-year free cash flow to debt coverage for Sutro Biopharma. For the full company profile including market capitalisation, see STRO market cap overview.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.55x $-188.44 Million $-191.54 Million $342.61 Million ▼ -64.6%
2023 -0.33x $-107.30 Million $-111.62 Million $321.09 Million ▼ -656.3%
2022 0.06x $11.41 Million $3.55 Million $189.90 Million ▲ +108.0%
2021 -0.75x $-66.36 Million $-81.68 Million $88.84 Million ▲ +23.6%
2020 -0.98x $-60.67 Million $-67.80 Million $62.06 Million ▲ +6.9%
2019 -1.05x $-61.54 Million $-65.02 Million $58.58 Million ▼ -775.8%
2018 0.16x $14.24 Million $12.68 Million $91.60 Million ▲ +169.0%
2017 -0.23x $-33.76 Million $-37.07 Million $149.77 Million ▼ -312.2%
2016 -0.05x $-8.76 Million $-13.15 Million $160.18 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities